CGBE Lectures - Transparency in the Pharmaceutical Industry

11.10.2018
08:00 am

Categories: Center for Corporate Governance & Business Ethics

Date: 11.10.2018
Time: 08:00 am
Location:


Date: 11.10.2018 
Time: 08.00 pm.
Location: FHWien der WKW, Währinger Gürtel 97, 1180 Vienna, Audimax
Registration                
Unsubscription                

Victoria Williams is Vice President and General Manager at GlaxoSmithKline Pharma GmbH (Austria). In her presentation, Mrs. Williams will focus on Transparency in the Pharmaceutical Industry. For more information, please refer to the abstract below. The lecture will be held in English.

This event is free of charge.

If you have any questions regarding the lecture series, please contact us at cgbe@fh-wien.ac.at.

Best regards,
Research Cluster SMEs & Family Businesses
Competence Center for Corporate Governance & Business Ethics


Abstract

I have worked in the commercial function of GlaxoSmithKline for the last 20 years across different countries in Europe. Although the pharmaceutical industry has contributed to many of the biggest breakthroughs in science, the reputation of the industry is one of the lowest across industry sectors. This has been because of several unfortunate and inexcusable industry scandals but also, I believe due to an innate societal suspicion of an industry that makes profit from illness.

Despite this, I am extremely proud of the industry I work in and believe we have an opportunity to address our poor reputation and focus on the cutting-edge science that is still leading to medical breakthroughs for many of the illnesses that affect our friends and family every day. However, we will never achieve this if we continue to work as an industry in the same way. I believe the key to affecting real change in trust and reputation is to be totally transparent about the relationship we have with prescribers of our medicines. GSK has been taking many steps towards uncompromised transparency for many years, e.g. fully disclosing clinical studies, the cooperation with patient groups and all interactions with HCPs on individual basis.

Across Europe the industry has taken significant steps forward in recent years in several countries and across the European Industry body, EFPIA (European Federation of Pharmaceutical Industries and Associations), with standards agreed and implemented in some localities. However, these are not routinely applied particularly on issues such as compulsory declaration of conflict of interests between Health Care Professionals and the Industry. My presentation aims to explore my belief that there is still considerable progress to be made if we want to address transparency and the reputation of the Pharma sector.


© Copyright 2018 FHW GmbH. Imprint